Dipeptidylpeptidase-4 Inhibitors (Gliptins)Focus on Drug-Drug Interactions

被引：0
|
作者：
André J. Scheen
机构：
[1] University of Liege,Division of Clinical Pharmacology and Division of Diabetes, Nutrition and Metabolic Disorders, Department of Medicine, CHU Sart Tilman
[2] CHU Sart Tilman (B35),Department of Medicine
来源：
Clinical Pharmacokinetics | 2010年 / 49卷
关键词：
Metformin; Digoxin; Simvastatin; Pioglitazone; Sulfonylurea;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Patients with type 2 diabetes mellitus (T2DM) are generally treated with many pharmacological compounds and are exposed to a high risk of drug-drug interactions. Indeed, blood glucose control usually requires acombination of various glucose-lowering agents, and the recommended global approachto reduce overall cardiovascular risk generally implies administration of several protective compounds, including HMG-CoA reductase inhibitors (statins), antihypertensive compounds and antiplatelet agents.
引用
收藏
页码：573 / 588
页数：15
相关论文
共 50 条
  • [1] Erratum to: Dipeptidylpeptidase-4 inhibitors (gliptins): focus on drug-drug interactions
    AJ Scheen
    [J]. Clinical Pharmacokinetics, 2011, 50 (1) : 74 - 74
  • [2] Dipeptidylpeptidase-4 Inhibitors (Gliptins): Focus on Drug-Drug Interactions (vol 49, pg 573, 2010)
    Scheen, Andre J.
    [J]. CLINICAL PHARMACOKINETICS, 2011, 50 (01) : 74 - 74
  • [3] Dipeptidylpeptitase-4 Inhibitors (Gliptins) Focus on Drug-Drug Interactions
    Scheen, Andre J.
    [J]. CLINICAL PHARMACOKINETICS, 2010, 49 (09) : 573 - 588
  • [4] Hypoglycemia Associated With Drug-Drug Interactions in Patients With Type 2 Diabetes Mellitus Using Dipeptidylpeptidase-4 Inhibitors
    Ray, Chin-Ying
    Wu, Victor Chien-Chia
    Wang, Chun-Li
    Tu, Hui-Tzu
    Huang, Yu-Tung
    Kuo, Chang-Fu
    Chang, Shang-Hung
    [J]. FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [5] Pharmacokinetics of dipeptidylpeptidase-4 inhibitors
    Scheen, A. J.
    [J]. DIABETES OBESITY & METABOLISM, 2010, 12 (08): : 648 - 658
  • [6] The role of dipeptidylpeptidase-4 inhibitors in management of cardiovascular disease in diabetes; focus on linagliptin
    Aroor, Annayya R.
    Manrique-Acevedo, Camila
    DeMarco, Vincent G.
    [J]. CARDIOVASCULAR DIABETOLOGY, 2018, 17
  • [7] The role of dipeptidylpeptidase-4 inhibitors in management of cardiovascular disease in diabetes; focus on linagliptin
    Annayya R. Aroor
    Camila Manrique-Acevedo
    Vincent G. DeMarco
    [J]. Cardiovascular Diabetology, 17
  • [8] Antimicrobial drug-drug interactions - Focus on fluoroquinolones
    Stein, GE
    [J]. FIRST INTERNATIONAL MOXIFLOXACIN SYMPOSIUM - BERLIN, 1999, 2000, : 127 - 129
  • [9] Evaluation of Pharmacokinetic Drug Interactions Between Gemigliptin (Dipeptidylpeptidase-4 Inhibitor) and Glimepiride (Sulfonylurea) in Healthy Volunteers
    Choi H.Y.
    Kim Y.H.
    Kim M.J.
    Lee S.H.
    Bang K.
    Han S.
    Lim H.-S.
    Bae K.-S.
    [J]. Drugs in R&D, 2014, 14 (3) : 165 - 176
  • [10] Pleiotropic effects of the dipeptidylpeptidase-4 inhibitors on the cardiovascular system
    Aroor, Annayya R.
    Sowers, James R.
    Jia, Guanghong
    DeMarco, Vincent G.
    [J]. AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 2014, 307 (04): : H477 - H492
12345